Citation data

Scopus by Title (Ref)

Articles that cite the referenced work, matched by title from the Scopus database.

10 resultsUpdated September 25, 2026

← Back to article

1

Modulation of CTLA-4, STAT3 and LAG-3 Expression by Ibrutinib and Idelalisib in Leukemic Cells of Patients with Chronic Lymphocytic Leukemia

Middle East Journal of Cancer

July 2026

Mousavi-Mirkalaei F.

2

JAK/STAT-mediated regulation of PD-L1 expression in breast cancer: Molecular mechanisms and implications for immunotherapy

Iscience

20 March 2026

Sang H.

Open Access

3

One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors

Cancer Cell International

December 2025

Dozandeh-Jouybari A.

Open Access

4

Inhibition of PI3K/AKT/mTOR signaling enhances autophagy in HL-60 acute myeloid leukemia cells: An integrative bioinformatic and in vitro study

Biochemistry and Biophysics Reports

December 2025

Malekan M.

Open Access

5

Effects of ibrutinib and venetoclax on the expression of immune checkpoint molecules in leukemic blasts of patients with acute lymphoblastic leukemia

Biochemistry and Biophysics Reports

June 2025

Dozandeh-Jouybari A.

Open Access

6

Effects of c-Kit Receptor, AKT, and NF-κB Inhibitors on Immune Evasion in Multiple Myeloma Cells

Iranian Journal of Allergy Asthma and Immunology

2025

Ranjbar A.

Open Access

7

Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia

Iranian Journal of Pharmaceutical Research

January - December 2025

Mousavi-Mirkalaei F.

Open Access

8

Thymol-loaded liposomes effectively induced apoptosis and decreased EGFR expression in colorectal cancer cells

Naunyn Schmiedeberg S Archives of Pharmacology

July 2024

Keshavarz F.

9

Ibrutinib topical delivery for melanoma treatment: The effect of nanostructured lipid carriers’ composition on the controlled drug skin deposition

Colloids and Surfaces B Biointerfaces

May 2024

Albuquerque L.F.F.

10

Combination therapy of acute myeloid leukemia by dual PI3K/mTOR inhibitor BEZ235 and TLR-7/8 agonist R848 in murine model

International Immunopharmacology

December 2023

Taghiloo S.